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In recent years a major leap fbrward has been made in diagnostic and therapeutic
options available for patients with HCM. In chapter 2, recently developed diagnostic
options and their current and potential use in patients with HCM are reviewed. A
large number of mutations in the B-myosin hear,y chain gene and some other genes
have been identif ied that cause HCM. Although it is today almost impossible to
diagnose HCM using routine genotyping in an individual patient, the genetic abnor-
rnality can be detected in about half of the families with HCM using l inkage studies.
The results of genetic screening in such families have shed new light on the value of
both the standard electrocardiogram and echocardiography in screening lbr HCM.
A significant overlap of electrocardiographic and echocardiographic findings is
present between genetically affected individuals and normal controls. Analysis of
hcart rate variabil ity and assessment of late potentials appear not useful in diagnos-
ing HCM or detecting high risk patients. The role of echocardiography in the man-
agement of patients with HCM has increased tremendously. Several structural ab-
normalit ies of the mitral valve leading to different therapeutic strategies can be de-
tected. Intraoperative transesophageal echocardiography can be very helpful in de-
cision making and in guiding the intervention. The role of QT interval dispersion,
magnetic resonance imaging and positron emissicln tomography are also reviewed in
chapter 2, but these subjects are discussed in greater detail in chapters 4 and 6-8.
In chapter 3, novel therapeutic options are discussed. The preferred medical therapy
for HCM is sti l l  verapamil, although B-blockers and disopyramide also have a role in
the treatment of patients with HCM. In recent years, to non-pharmacologic treat-
ment modalit ies other than surgery have been developed that both have in common
an induction of a remodell ing process of the left ventricle. Outflow tract obstruction
can be eliminated by injecting absolute alcohol into the tirst major septal artery, but
major concern exists on the long term effects of this method. Permanent dual cham-
ber pacing improves subjective symptoms in about 80 % of patients with drug refrac-
tory obstructive HCM, but again it is not clear if this therapeutic option might show
detrimental on the long run.
In chapter 4, the diagnostic value of spin-echo magnetic resonance imaging y tran-
sthoracic echocardiography is compared. In 52 patients with HCM 2 hypertrophy
scores are assessed with botlt techniques. The hypertrophy scores correlate well be-
fween echocardiography and magnetic resonance imaging, but echocardiography is
of insufficient quality for calculating adequate hypertrophy scores in a substantial
part of the patients. magnetic resonance imaging provides the most comprehensive
diagnostic information in patients with HCM.
In chapter 5, the etfects of acute intravenous v long-term oral verapamil administra-
tion on diastolic function are noted. Both modes of administration have distinctly
different results with respect to diastolic function. After oral verapamil adrninistra-
tion, left ventricular diastolic tunction improved in most patients, but alier intrave-
nous administration no consistent improvement was noted. It is not possible to pre-
t02
dict the etfect of long-term oral verapamil with an intravenous test dose in an indi-
vidual patient with HCM.
In chaptets 6 and7, the elfects of permanent dual-chamber pacing on myocardial
perfusion in patients with HCM are noted. Pacing results in clinical improvement
and a reduction of anginal complaints. During pacing, a decrease of resting left ven-
tricular myocardial blood flow and blood flow during pharmacologically induced
coronary vasodilation is found. Global perfusion reserve is unchanged, but myocar-
dial perfusion reserye shifts into a nore homogeneous distribution. These effects of
pacing are probably caused by a reduction in anteroseptal f iber strain and oxygen
demand due to early septal activation.
In chapter 8, QT dispersion and the occurrence of late potentials are assessed. The
incidence of late potentials in patients with HCM is low. QT dispersion is increased
and QT interval prolonged but both are not related to the occurrence of ventricular
arrhythmias. The electrocardiographic manifestations of delayed conduction and
abnormal repolarisation are probably blunted in patients with septal forms of HCM
due to the early activation of the septum.
In conclusion, the most pronrising diagnostic tools in patients with HCM are genet-
ics, magnetic resonance imaging and positron emission tomography. These techniques
may add additional information necessary for a reliable risk stratif ication in patients
with HCM. Of the therapeutic options the effects of dual-chamber pacing are hope-
ful, but cautious optimism is warranted unti l more l ight is shed on the exact effects of
pacing on the pathophysiology and on the long-term effects.
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